1. Home
  2. CREV vs CDT Comparison

CREV vs CDT Comparison

Compare CREV & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Carbon Revolution Public Limited

CREV

Carbon Revolution Public Limited

HOLD

Current Price

$2.53

Market Cap

3.1M

Sector

N/A

ML Signal

HOLD

Logo Conduit Pharmaceuticals Inc.

CDT

Conduit Pharmaceuticals Inc.

HOLD

Current Price

$1.43

Market Cap

2.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CREV
CDT
Founded
2007
2019
Country
Australia
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1M
2.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CREV
CDT
Price
$2.53
$1.43
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
141.7K
388.8K
Earning Date
01-30-2026
03-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$47,677,475.00
N/A
Revenue This Year
$40.32
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
86.77
N/A
52 Week Low
$1.48
$1.43
52 Week High
$9.45
$2,198.40

Technical Indicators

Market Signals
Indicator
CREV
CDT
Relative Strength Index (RSI) 56.65 36.47
Support Level $1.57 $1.61
Resistance Level $1.77 $1.75
Average True Range (ATR) 0.30 0.16
MACD 0.12 -0.01
Stochastic Oscillator 69.96 0.55

Price Performance

Historical Comparison
CREV
CDT

About CREV Carbon Revolution Public Limited

Carbon Revolution PLC is an Australian-based technology company manufacturing carbon fiber wheels. It is an OEM supplier and a world-wide manufacturer of lightweight technology carbon fibre wheels to the automotive industry. The Company supplies wheels to OEMs across the globe for luxury and high-performance vehicles and SUVs, and is developing wheels for electric vehicles under contract for its OEM customers. The company generates maximum revenue Internationally.

About CDT Conduit Pharmaceuticals Inc.

CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Share on Social Networks: